TScan Therapeutics FY Conference Summary Company Overview - **Company**: TScan Therapeutics (NasdaqGM:TCRX) - **Industry**: Clinical stage biotechnology focused on TCRT cell therapies for cancer treatment - **Key Participants**: Gavin MacBeath (CEO), Li Chun (Quarterly Research Associate) [1][2] Core Programs and Clinical Data - **Clinical Programs**: - Heme malignancies targeting residual cancer post-bone marrow transplants - Solid tumors utilizing multiplex therapy to address tumor heterogeneity [2][3] - **Lead Program**: Heme malignancies with promising clinical data showing an 8% relapse rate (2 out of 26 patients) compared to 33% in a control arm (4 out of 12 patients) [3][19] - **Upcoming Milestones**: - Updated data presentation at a medical conference at the end of the year - Launch of pivotal study and dosing of the first patient in 2025 [3][4] Financial Position - **Cash Position**: Ended Q2 with $218 million, providing a runway into Q1 2027 [4] Mechanism of Action - **TCRT Cell Therapy**: Targets specific antigens presented by tumor cells, utilizing engineered T cells to selectively eliminate residual cancer cells post-transplant [5][10] Patient Characteristics and Study Design - **Patient Demographics**: - Treatment arm: 81% high-risk patients - Control arm: 77% high-risk patients [12] - **Study Design**: Phase one study included a control arm to compare relapse rates, with a well-matched patient population [11][13] Safety and Efficacy - **Adverse Events**: No significant increase in adverse events compared to control; manageable cases of CRS (Cytokine Release Syndrome) reported [14][19] - **Chimerism Data**: Higher rates of complete donor chimerism in treatment arm compared to control, indicating better outcomes [16][17] Market Opportunity - **Addressable Market**: Approximately 9,000 patients with AML, MDS, and ALL undergo allogeneic transplants annually in the U.S. and Europe [22] - **Potential Expansion**: If clinical practice shifts towards haploidentical transplants with TScan's product, the addressable market could increase to over 5,000 patients annually [24][25] Solid Tumor Program - **Strategy**: Development of multiplex therapy to target multiple antigens in heterogeneous solid tumors, with initial data expected in Q1 next year [26][27] Autoimmunity Research - **Collaboration with Amgen**: Ongoing program to identify targets in Crohn's disease and other autoimmune disorders, with data presentation planned for later this year [28][29] Future Plans - **Pivotal Study Launch**: Scheduled for this year with TSC-101, alongside filing INDs for expansion TCRs [29] - **Data Updates**: Plans to present two-year data from the phase one study and initial safety data from multiplex therapy in Q1 next year [29] Conclusion - TScan Therapeutics is positioned to advance its innovative TCRT cell therapies with significant clinical data supporting its heme malignancy program and a robust pipeline for solid tumors and autoimmune diseases, indicating strong potential for future growth and market impact [30]